{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:56:20Z","timestamp":1781844980547,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The science and technology project of Cangnan County","award":["(2021S06"],"award-info":[{"award-number":["(2021S06"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cephaeline (CPL), a bioactive compound derived from the medicinal plant Ipecacuanha, has demonstrated inhibitory effects on several tumor types. Nevertheless, its role in breast cancer and the underlying molecular mechanisms remain largely unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This research aimed to investigate the anti-cancer potential of CPL in breast cancer cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The IC50 of CPL was determined using the CCK-8 assay. Subsequently, the effects of CPL on cell migration and proliferation were assessed through wound healing (scratch) and colony formation assays, respectively. Additionally, MDA and GSH levels were quantified using ELISA, while ROS production was visualized via DHE staining. Intracellular iron content was measured using an iron assay kit. Furthermore, the expression levels of p53, SLC7A11, and GPX4 were evaluated using Western blot. All experiments were performed in triplicate and independently repeated at least three times, and data were analyzed using Student\u2019s t-test or one-way ANOVA, as appropriate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CPL significantly inhibited the proliferation and viability of 4T1 and MDA-MB-231 breast cancer cells in a dose-dependent manner, with IC50 values of 38.89\u00a0nM and 50.29\u00a0nM, respectively, and concomitantly suppressed cell migration and colony formation at higher concentrations. It also increased intracellular MDA and ROS and downregulated GSH, SLC7A11 and GPX4, inducing ferroptosis. siRNA knockdown of p53 attenuated CPL's effects, indicating p53's key role in CPL's anti-cancer activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides evidence that CPL exerts anti-breast cancer effects by promoting ferroptosis through the p53\/SLC7A11\/GPX4 axis, highlighting its therapeutic potential as a novel agent for cancer treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40199-026-00619-9","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:44:27Z","timestamp":1781844267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cephaeline promotes ferroptosis in breast cancer via\u00a0p53\/SLC7A11\/GPX4 axis"],"prefix":"10.1007","volume":"34","author":[{"given":"Xiaohong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudiao","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"10074","key":"619_CR1","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","volume":"389","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, et al. Breast cancer. Lancet. 2017;389(10074):1134\u201350.","journal-title":"Lancet"},{"issue":"1","key":"619_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40659-017-0140-9","volume":"50","author":"M Akram","year":"2017","unstructured":"Akram M, et al. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33.","journal-title":"Biol Res"},{"issue":"17","key":"619_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174287","volume":"13","author":"S \u0141ukasiewicz","year":"2021","unstructured":"\u0141ukasiewicz S, et al. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel). 2021;13(17):4287.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"619_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","volume":"22","author":"F Ye","year":"2023","unstructured":"Ye F, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22(1):105.","journal-title":"Mol Cancer"},{"issue":"4","key":"619_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, et al. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"619_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41569-022-00735-4","volume":"20","author":"X Fang","year":"2023","unstructured":"Fang X, et al. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat Rev Cardiol. 2023;20(1):7\u201323.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"619_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","volume":"31","author":"D Tang","year":"2021","unstructured":"Tang D, et al. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31(2):107\u201325.","journal-title":"Cell Res"},{"key":"619_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.freeradbiomed.2025.05.393","volume":"237","author":"N Noguchi","year":"2025","unstructured":"Noguchi N, et al. Lipid peroxidation, ferroptosis, and antioxidants. Free Radic Biol Med. 2025;237:228\u201338.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"619_CR9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","volume":"7","author":"W Gao","year":"2022","unstructured":"Gao W, et al. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Signal Transduct Target Ther. 2022;7(1):196.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"619_CR10","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41419-022-05444-x","volume":"13","author":"J Zhang","year":"2022","unstructured":"Zhang J, et al. Endoplasmic reticulum stress-mediated cell death in liver injury. Cell Death Dis. 2022;13(12):1051.","journal-title":"Cell Death Dis"},{"issue":"1","key":"619_CR11","doi-asserted-by":"publisher","first-page":"188556","DOI":"10.1016\/j.bbcan.2021.188556","volume":"1876","author":"LJ Hern\u00e1ndez Borrero","year":"2021","unstructured":"Hern\u00e1ndez Borrero LJ, et al. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188556.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"8","key":"619_CR12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","volume":"20","author":"AJ Levine","year":"2020","unstructured":"Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20(8):471\u201380.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"619_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41419-024-06783-7","volume":"15","author":"Y Guo","year":"2024","unstructured":"Guo Y, et al. Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance. Cell Death Dis. 2024;15(6):412.","journal-title":"Cell Death Dis"},{"issue":"5","key":"619_CR14","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","volume":"29","author":"K Engeland","year":"2022","unstructured":"Engeland K. Cell cycle regulation: p53\u2013p21-RB signaling. Cell Death Differ. 2022;29(5):946\u201360.","journal-title":"Cell Death Differ"},{"key":"619_CR15","doi-asserted-by":"crossref","unstructured":"Hao Q, et al. The ARTS of p53-dependent mitochondrial apoptosis. J Mol Cell Biol. 2023;14(10):mjac074.","DOI":"10.1093\/jmcb\/mjac074"},{"key":"619_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.freeradbiomed.2018.05.074","volume":"133","author":"R Kang","year":"2019","unstructured":"Kang R, et al. The tumor suppressor protein p53 and the ferroptosis network. Free Radic Biol Med. 2019;133:162\u20138.","journal-title":"Free Radic Biol Med"},{"issue":"8","key":"619_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula P, et al. Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12(8):599\u2013620.","journal-title":"Protein Cell"},{"issue":"3","key":"619_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/cdd.2015.158","volume":"23","author":"Y Xie","year":"2016","unstructured":"Xie Y, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23(3):369\u201379.","journal-title":"Cell Death Differ"},{"issue":"1","key":"619_CR19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/13880209.2024.2359105","volume":"62","author":"J Yuan","year":"2024","unstructured":"Yuan J, et al. Traditional Chinese medicine for breast cancer treatment: a bibliometric and visualization analysis. Pharm Biol. 2024;62(1):499\u2013512.","journal-title":"Pharm Biol"},{"issue":"1","key":"619_CR20","doi-asserted-by":"publisher","first-page":"e138856","DOI":"10.5812\/ijpr-138856","volume":"22","author":"S Sarmoko","year":"2023","unstructured":"Sarmoko S, et al. Different Modes of Mechanism of Gamma-Mangostin and Alpha-Mangostin to Inhibit Cell Migration of Triple-Negative Breast Cancer Cells Concerning CXCR4 Downregulation and ROS Generation. Iran J Pharm Res. 2023;22(1):e138856.","journal-title":"Iran J Pharm Res"},{"issue":"1","key":"619_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41375-019-0513-x","volume":"34","author":"DY Yosifov","year":"2020","unstructured":"Yosifov DY, et al. Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. Leukemia. 2020;34(1):115\u201327.","journal-title":"Leukemia"},{"issue":"5","key":"619_CR22","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1002\/ptr.7833","volume":"37","author":"M Valipour","year":"2023","unstructured":"Valipour M, et al. Dual action anti-inflammatory\/antiviral isoquinoline alkaloids as potent naturally occurring anti-SARS-CoV-2 agents: a combined pharmacological and medicinal chemistry perspective. Phytother Res. 2023;37(5):2168\u201386.","journal-title":"Phytother Res"},{"issue":"6","key":"619_CR23","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/jop.13252","volume":"51","author":"LC Silva","year":"2022","unstructured":"Silva LC, et al. Cephaeline is an inductor of histone H3 acetylation and inhibitor of mucoepidermoid carcinoma cancer stem cells. J Oral Pathol Med. 2022;51(6):553\u201362.","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"619_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/13880209.2024.2309891","volume":"62","author":"P Chen","year":"2024","unstructured":"Chen P, et al. Cephaeline promotes ferroptosis by targeting NRF2 to exert anti-lung cancer efficacy. Pharm Biol. 2024;62(1):195\u2013206.","journal-title":"Pharm Biol"},{"issue":"11","key":"619_CR25","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41419-024-07169-5","volume":"15","author":"X Qiao","year":"2024","unstructured":"Qiao X, et al. Combined metformin and simvastatin therapy inhibits SREBP2 maturation and alters energy metabolism in glioma. Cell Death Dis. 2024;15(11):809.","journal-title":"Cell Death Dis"},{"issue":"3","key":"619_CR26","doi-asserted-by":"publisher","first-page":"368504251367649","DOI":"10.1177\/00368504251367649","volume":"108","author":"Q Li","year":"2025","unstructured":"Li Q, et al. TBC1D24 promotes the progression of the breast cancer cells via ARF6\/PLD axis under hypoxia. Sci Prog. 2025;108(3):368504251367649.","journal-title":"Sci Prog"},{"key":"619_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fcell.2019.00107","volume":"7","author":"J Pijuan","year":"2019","unstructured":"Pijuan J, et al. In vitro Cell Migration, Invasion, and Adhesion Assays: From Cell Imaging to Data Analysis. Front Cell Dev Biol. 2019;7:107.","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"619_CR28","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.1038\/s41596-021-00615-0","volume":"16","author":"N Brix","year":"2021","unstructured":"Brix N, et al. Analysis of clonogenic growth in vitro. Nat Protoc. 2021;16(11):4963\u201391.","journal-title":"Nat Protoc"},{"issue":"1","key":"619_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/2211738507666190122111224","volume":"7","author":"FA Fisusi","year":"2019","unstructured":"Fisusi FA, et al. Drug combinations in breast cancer therapy. Pharm Nanotechnol. 2019;7(1):3\u201323.","journal-title":"Pharm Nanotechnol"},{"issue":"4","key":"619_CR30","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker AB, et al. Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell. 2020;37(4):496\u2013513.","journal-title":"Cancer Cell"},{"issue":"1","key":"619_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","volume":"19","author":"B Asselain","year":"2018","unstructured":"Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordstr\u00f6m E, Bliss J, et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27\u201339.","journal-title":"Lancet Oncol"},{"issue":"7","key":"619_CR32","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, et al. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22(7):381\u201396.","journal-title":"Nat Rev Cancer"},{"key":"619_CR33","doi-asserted-by":"crossref","unstructured":"Shen M, et al. DNAJC12 causes breast cancer chemotherapy resistance by repressing doxorubicin-induced ferroptosis and apoptosis via activation of AKT. Redox Biol. 2024;70:103035, 103035.","DOI":"10.1016\/j.redox.2024.103035"},{"key":"619_CR34","doi-asserted-by":"crossref","unstructured":"Li J, Li Y, et al. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1\/miR-195-5p axis-dependent manner in hepatocellular carcinoma. J Exp Clin Cancer Res. 2024;43(1):143.","DOI":"10.1186\/s13046-024-03061-4"},{"issue":"11","key":"619_CR35","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1038\/s41418-025-01528-1","volume":"32","author":"R Gong","year":"2025","unstructured":"Gong R, et al. GPX4-AUTAC induces ferroptosis in breast cancer by promoting the selective autophagic degradation of GPX4 mediated by TRAF6-p62. Cell Death Differ. 2025;32(11):2022\u201337.","journal-title":"Cell Death Differ"},{"key":"619_CR36","doi-asserted-by":"crossref","unstructured":"Li G, Li X, et al. Identification of hub genes and small molecule drugs associated with acquired resistance to gefitinib in non-small cell lung cancer. J Cancer. 2021;12(17):5286\u201395.","DOI":"10.7150\/jca.56506"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00619-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00619-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00619-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:44:35Z","timestamp":1781844275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00619-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["619"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00619-9","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"8 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}